BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/380/0.1/20.09.24

BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/380/0.1/20.09.24 Share Price

DE000VD3YFX4

Market Closed - Boerse Frankfurt Warrants 18:52:10 27/06/2024 BST
0.141 ^EUR	+11.02%

Current month	-71.22%
1 month	-53.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/380/0.1/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	06-27	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	06-25	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	06-24	MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	06-21	MT

More news

Quotes 5-day view

Date	Price	Change
27/06/24	0.141	+11.02%
26/06/24	0.127	-14.77%
25/06/24	0.149	+8.76%
24/06/24	0.137	-34.13%
21/06/24	0.208	+26.83%

Real-time Boerse Frankfurt Warrants

Last update June 27, 2024 at 06:52 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Vontobel
WKN	VD3YFX
ISIN	DE000VD3YFX4
Date issued	11/04/2024
Strike	380 $
Maturity	20/09/2024 (85 Days)
Parity	10 : 1
Emission price	2 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	2.23 €
Lowest since issue	0.071 €
Spread	0.034 €
Spread %	20.36%

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company